Related Experiment Videos
Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas
C Guglielmi1, M Martelli, M Federico
1Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, via Benevento 6, 00161 Roma, Italy. guglielmi@bce.med.uniroma1.it
Haematologica
|September 5, 2001
Summary
Identifying risk factors for diffuse large cell lymphoma (DLCL) relapse is crucial. Poor performance status, advanced stage, and elevated LDH at relapse are key adverse prognostic factors.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Diffuse large cell lymphoma (DLCL) is an aggressive non-Hodgkin lymphoma.
- Identifying prognostic factors at first relapse is critical for treatment planning.
Purpose of the Study:
- To identify independent risk factors associated with overall survival (OS) and progression-free survival (PFS) in adults with DLCL at first relapse.
- To develop a prognostic index for DLCL at first relapse.
Main Methods:
- A cohort of 474 adult patients with DLCL at first relapse was studied across 45 centers in Italy.
- Patients received various salvage therapies, including high-dose chemotherapy with stem cell transplant in 20%.
- Cox models were used to analyze factors influencing OS and PFS, adjusted for salvage therapy.
Main Results:
- Overall response rate was 63%, with 3-year OS of 35% and 3-year PFS of 26%.
- Independent adverse prognostic factors for OS and PFS included relapse within 12 months of diagnosis, elevated lactate dehydrogenase (LDH), advanced stage, and poor performance status.
- A cumulative adverse factor index was developed, identifying distinct risk groups and predicting outcomes.
Conclusions:
- Time from diagnosis to relapse, LDH levels, disease stage, and performance status at relapse are important considerations in comparative studies of DLCL salvage therapy.
- Approximately one-third of patients with more than two adverse factors require more effective salvage treatments.